Sumitomo Chemical Company, Limited

Sumitomo Pharmaceuticals Company Limited

Sharp Kabushiki Kaisha Corporation

Ltt Bio-pharma Co., Ltd.

Diaclone

Biotest Pharma Gbmh

Hiroshi Noguchi

Katsuzo Kamoshita

Toshiro Kato

Junya Takahashi

Hisao Tobiki

Toshiaki Komatsu

Shigeo Yamamoto

Hirotada Yamada

Takenari Nakagome

Kozo Shimago

Yasuko Eda

Akio Izawa

Yukio Oguri

Kenji Irie

Norihiko Tanno

Iwao Nakatsuka

Shigeru Okano

Mutsuo Taiji

Chikao Nakayama

Shunichi Hashimoto

Takashi Matsuo

Shigeyoshi Kitamura

Yukio Ishiguri

Akihiko Mine

Kosaku Okamura

Junji Ichihara

Ryo Yoshida

Seizo Sumida

Hiroshi Ochi

Kousaku Okamura

Masazumi Terashima

Hiroshi Ohtsuka

Shinichi Yokota

Michiko Kishino

Hisao Yamamoto

Shigeho Inaba

Michihiro Yamamoto

Naonori Hirata

Yutaka Mizushima

Mitsuru Sasaki

Masao Koshiba

John Wijdenes

Toru Kimura

Shigeaki Morooka

Kaoru Kikuchi

Rie Igarashi

Takao Okuda

Masuhiro Kato

Hiroshi Yamaga

Hideyuki Gomi

Yasushi Itakura

Yasuyoshi Kurokawa

Ikuko Uezumi

Eiyoshi Itooka

Akira Ito

Kiyokazu Jimpo

Yoko Ishige

Makoto Inoue

Tomoyuki Nakatani

Modified BDNF having improved pharmacological activities, pharmacokinetics and physical properties can be obtained by modifying BDNF with a 1-acyl-glycerol derivative. This BDNF being modified with a 1-acyl-glycerol derivative of the present invention has more efficacious and more excellent pharmacokinetic properties with retaining the useful effects being characteristic to BDNF which are useful as remedies for neurodegenerative diseases and diabetes mellitus, and hence, it is particularly useful as a therapeutic agent for treatment of type 2 diabetes mellitus.

Modified BDNF

The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4/5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.

Hepatocyte growth factor for treatment of diabetes

L-ascorbic acid, L-ascorbic acid derivatives and salts thereof can reduce lactic acid levels in blood, and are useful for treating lactic acidosis and the like caused by administration of amoxapine, theophylline, metformin, phenformin, buformin, nalidixic acid, hopantenic acid, azidothymidine, dideoxycytidine, high caloric transfusion, propylene glycol, ethylene glycol, xylitol, lactose, sorbitol or the like.

Composition containing ascorbic acid

Remedies for diabetes

Factors mutated in the D1 cap region

Humanized B-B10

A human monoclonal antibody, which has prophylactic and therapeutic effect to infections diseases caused by Pseudomonas aeruginosa, and the epitope of which is located in the outer core moiety of LPS of the microorganism. A hybridoma producing the human monoclonal antibody, and processes for preparing the antibody and hybridoma are also provided.

Human monoclonal antibody and hybridoma producing the same

A human monoclonal antibody, which has prophylactic and therapeutic effect to infectious diseases caused by Pseudomonas aeruginosa of serotypes A and H classified under the Japanese Committee's Classification, and the epitope of which is located at the common structure in the O-antigen of Pseudomonas aeruginosa of serotypes A and H. A hybridoma producing said human monoclonal antibody, and processes for preparing said hybridoma and antibody are also provided.

Human monoclonal antibody, and its production and use

A compound of the formula: ##STR1## useful as a fungicidal agent against phytopathogenic fungi, particularly their strains resistant to benzimidazole, thiophanate and/or cyclic imide fungicides.

Fungicidal aniline derivatives

A fungicidal composition which comprises as an active ingredient a compound of the formula: ##STR1## wherein X is a halogen atom, a C.sub.1 -C.sub.3 alkyl group or a C.sub.1 -C.sub.3 alkoxy group, and an inert carrier or diluent.

Fungicidal composition employing nitrobenzene derivatives

A compound of the formula: ##STR1## useful as a fungicidal agent against phytopathogenic fungi, particularly strains thereof which are resistant to benzimidazole or thiophanate fungicides and/or cyclic imide fungicides.

A compound of the formula: ##STR1## useful as a fungicidal agent against phytopathogenic fungi, particularly their strains resistance to benzimidazole or thiophanate fungicides and/or cyclic imide fungicides.

Fungicidal N-pyridinylamide derivatives

Use of an anilide of the formula: ##STR1## as a fungicidal agent against phytophatogenic fungi, particularly their strains resistant to benzimidazole thiophanate fungicides and/or cyclic imide fungicides.

Fungicidal anilides

A compound of the formula: ##STR1## useful as a fungicidal agent against phytopathogenic fungi, particularly their strains resistant to benzimidazole and thiophanate fungicides and/or cyclic imide fungicides.

A compound of the formula: ##STR1## useful as a fungicidal agent against phytopathogenic fungi, and particularly against strains resistant to benzimidazole, thiophanate and/or cyclic imide fungicides.

Growing community of inventors

Toyonaka, Japan

Hiroshi Noguchi